



The Challenges and Therapeutic Prospects in Autoimmune Diseases

Guest Editors:

Prof. Dr. Cristian Baicus

Department of Internal Medicine,
Colentina Clinical Hospital, Carol
Davila University of Medicine and
Pharmacy Bucharest, Bucharest,
Romania

Dr. Camelia Badea

Department of Internal Medicine,
Colentina Clinical Hospital, Carol
Davila University of Medicine and
Pharmacy Bucharest, Bucharest,
Romania

Dr. Razvan Adrian Ionescu

Department of Internal Medicine,
Colentina Clinical Hospital, Carol
Davila University of Medicine and
Pharmacy Bucharest, Bucharest,
Romania

Deadline for manuscript
submissions:

closed (25 March 2024)

Message from the Guest Editors

Autoimmune diseases are rare diseases with single-organ or multisystemic impact that can cause a lot of damage. Moreover, being rare diseases, most of the time there is no valid evidence concerning their treatment. Frequently, there is no accurate test for their diagnosis either, and the diagnosis is made using far from perfect criteria, or by exclusion.

The treatment landscape of this kind of disease has evolved during the last 25 years, as new knowledge and new technologies have emerged that led to the appearance of new drug classes. Nevertheless, as the treatment of autoimmune diseases almost always involves immunosuppressive drugs, patients may easily contract infections, and sometimes it is hard to differentiate the infection from a disease flare-up. This raises other problems with respect to the treatment of such patients.

These are some of the challenges of autoimmune diseases. This Special Issue welcomes original research papers, systematic reviews, or narrative reviews addressing fundamental, translational, and clinical aspects from this domain.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. David Alan Rizzieri

1. Novant Health Cancer
Institute, Winston-Salem, NC
27103, USA
2. Division of Hematologic
Malignancies and Cellular
Therapy, Duke University,
Durham, NC 27710, USA

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, ‘omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, and other databases.

Journal Rank: JCR - Q1 (Medicine, General and Internal) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Journal of Personalized Medicine
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/jpm
jpm@mdpi.com
[X@JPM_MDPI](https://twitter.com/JPM_MDPI)